|
KMID : 1144520180300030206
|
|
Knee Surgery & Related Research
2018 Volume.30 No. 3 p.206 ~ p.214
|
|
|
Intra-Articular Injection of Bone Marrow-Derived Mesenchymal Stem Cells Leading to Better Clinical Outcomes without Difference in MRI Outcomes from Baseline in Patients with Knee Osteoarthritis
|
|
Shin Young-Soo
Yoon Jung-Ro
Kim Hee-Sun
Lee Seon-Heui
|
|
|
Abstract
|
|
|
Purpose: Bone marrow (BM) is frequently used as a source of mesenchymal stem cells (MSCs) because they have a high potential for differentiation. However, it is unclear whether BM-derived MSCs lead to better clinical and magnetic resonance imaging (MRI) outcomes postoperatively.
Materials and Methods: This meta-analysis compared the clinical and MRI outcomes in patients with knee osteoarthritis (OA) treated with BM-derived MSCs. Eight studies comparing the clinical and MRI outcomes assessed with various measurement tools in patients with knee OA treated with BM-derived MSCs were included.
Results: The range of motion (95% confidence interval [CI], -13.05 to 4.24; p=0.32) and MRI outcomes (95% CI, -0.16 to 1.40; p=0.12) did not differ significantly between the baseline and final follow-up. In contrast, pain (95% CI, 0.89 to 1.87; p＜0.001) and functional outcomes (95% CI, 0.70 to 2.07; p＜0.001) were significantly improved at the final follow-up when compared to the baseline.
Conclusions: This meta-analysis found no significant difference in the tested range of motion and MRI outcomes between the baseline and the final follow-up in patients treated with BM-derived MSCs, whereas significant functional improvement and pain relief were noted when compared with the baseline. Thus, BM-derived MSCs appear to be a viable alternative for patients with knee OA, although long-term and high-quality randomized controlled trials are needed to confirm the clinical benefits.
|
|
|
KEYWORD
|
|
|
Knee, Osteoarthritis, Bone marrow, Mesenchymal stem cells, Meta-analysis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|